Abiopharma

Management and officers – staffing as of 16.8.26

The company’s liability balance as of 30.6.26, by maturity dates

Update on eVOLVE-Lung02 Phase III trial

Financial Reports Presentation for Q2 2026

General Announcement: Transaction in own shares

Tagrisso+Orpathys improved PFS & OS in EGFRm lung

Q2/semi-annual report for 2026

Investors presentation - August 2026

Immediate Report

Investor presentation second quarter 2026

Q2 2026 report - iXBRL report

Events and transactions

FLSmidth: Transactions under share buy-back programme

Dividend in the amount of 274.1765 agorot per share, ex-date 24.8.26, payment 31.8.26

Register of shareholders, changes and capital status – exercise of warrants